Resource impact statement

Cancer Drugs Fund technology

NICE has recommended ribociclib with fulvestrant for use within the Cancer Drugs Fund for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy only if exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor.

Ribociclib with fulvestrant will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Novartis have a commercial access agreement that makes ribociclib with fulvestrant available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of ribociclib with fulvestrant will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires (December 2020) or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.

It is estimated that up to 3,300 people per year with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy are eligible for treatment with ribociclib with fulvestrant.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 14 August 2019